Category: NOXA12
-
™E Pharma Announces Oral Presentation of NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma at ESMO Congress 2024 By Investing.com
•
Berlin-(Business):™E Pharma NV (Euronext Growth Paris: AL™E), A clinical-stage biotechnology company focused on developing novel therapies to treat cancer by targeting the tumor environ- ment (E™), today announced that an abstract including results from the NOX-A12 GLORIA Phase 1/2 trial in first-line brain cancer (glioblastoma) has been selected for presentation…